Investors should await topline results from SUNRISE-PD and ADDRESS-LC trials in mid-2026, which could serve as major value inflection points. The AAN abstract presentation may increase scientific visibility but does not change the current risk profile.
Price Chart
Executive Summary
BioVie announced the acceptance of an abstract presenting baseline data from its SUNRISE-PD Phase 2 trial of bezisterim in early Parkinson’s disease for presentation at the 2026 American Academy of Neurology (AAN) meeting. Topline results from the study are expected in mid-2026.
Key Facts
- Abstract from the SUNRISE-PD study on bezisterim accepted for poster presentation at the AAN annual meeting (April 18–22, 2026).
- SUNRISE-PD enrolled 60 patients to evaluate bezisterim monotherapy in early Parkinson’s disease; topline results expected mid-2026.
- Bezisterim is also being studied in Long COVID (ADDRESS-LC trial, ~200 patients) and Alzheimer’s disease, with topline data also expected mid-2026.
- No new clinical efficacy or safety data was released—this announcement reflects progress in trial execution and scientific visibility.
Financial Impact
No immediate financial impact; this is a developmental milestone.
Risk Factors
- Clinical trial results may not meet expectations, particularly given the high failure rate in neurodegenerative drug development.
- BioVie has limited market capitalization ($10M) and may face challenges in funding late-stage trials or commercialization without partnerships or dilutive financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273252 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.37 | awaiting T+20 | — | $1.33 (−2.92%) |
Sep 15, 2026 5w ago | Press Release | $1.75 $1.20 | ▼ −31.43% | ▼ −34.41% | $1.33 (−24.00%) |
Aug 14, 2026 10w ago | S-1/A | $1.17 $1.75 | ▼ −49.57% | ▼ −51.55% | $1.33 (−13.68%) |
Aug 6, 2026 11w ago | S-1/A | $1.35 $2.03 | ▼ −50.37% | ▼ −49.77% | $1.33 (+1.48%) |
Aug 6, 2026 11w ago | 8-K | $1.35 $2.03 | ▲ +50.37% | ▲ +49.77% | $1.33 (−1.48%) |
Jul 31, 2026 12w ago | S-1/A | $1.62 $2.28 | ▼ −40.74% | ▼ −39.50% | $1.33 (+17.90%) |
Jun 30, 2026 16w ago | EFFECT | $1.94 $1.37 | ▲ +29.38% | ▲ +28.35% | $1.33 (+31.44%) |
Apr 27, 2026 26w ago | Press Release | $1.59 $1.44 | ▼ −9.43% | ▼ −14.39% | $1.33 (−16.35%) |
Apr 14, 2026 27w ago | Press Release | $1.46 $1.35 | ▼ −7.53% | ▼ −13.83% | $1.33 (−8.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers